Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.59 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.59 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.55 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL1697430 | 1.00 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL8722666 | 0.99 | SLC28A1 (0.59) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL3498449 | 0.95 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL3620601 | 0.94 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL1835845 | 0.92 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL3684420 | 0.92 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL4953755 | 0.88 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL1697431 | 0.88 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL11424489 | 0.85 | P2RY2 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL21295128 | 0.85 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 844 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028668-A1 | DETECTION OF BASE MODIFICATIONS BY ENHANCING ELECTRICAL CONTRAST IN NANOPORES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-01-29 | — | — | US | claimed |
| US-20260022424-A1 | NUCLEIC ACID METHYLATION PROFILING METHOD | GUARDANT HEALTH INC (US) | 2026-01-22 | — | — | US | claimed |
| US-20260015668-A1 | COMPOSITION AND METHODS RELATED TO MODIFICATION OF 5 HYDROXYMETHYLCYTOSINE (5-hmC) | THE UNIVERSITY OF CHICAGO (US) | 2026-01-15 | — | — | US | claimed |
| EP-4655416-A1 | NUCLEIC ACID METHYLATION PROFILING METHOD | Guardant Health, Inc. (US) | 2025-12-03 | — | — | EP | claimed |
| EP-4565717-A1 | DETECTION OF BASE MODIFICATIONS BY ENHANCING ELECTRICAL CONTRAST IN NANOPORES | Ramot at Tel-Aviv University Ltd. (IL) | 2025-06-11 | — | — | EP | claimed |
| WO-2024159053-A1 | NUCLEIC ACID METHYLATION PROFILING METHOD | GUARDANT HEALTH, INC. (US) | 2024-08-02 | — | — | WO | claimed |
| US-20240209430-A1 | METHODS FOR THE AMPLIFICATION OF BISULFITE-TREATED DNA | THE UNIVERSITY OF CHICAGO (US) | 2024-06-27 | — | — | US | claimed |
| WO-2024028866-A1 | DETECTION OF BASE MODIFICATIONS BY ENHANCING ELECTRICAL CONTRAST IN NANOPORES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-02-08 | — | — | WO | claimed |
| US-20210310062-A1 | METHODS FOR THE AMPLIFICATION OF BISULFITE-TREATED DNA | THE UNIVERSITY OF CHICAGO (US) | 2021-10-07 | — | — | US | claimed |
| US-11091793-B2 | Detection of hydroxymethylcytosine bases | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2021-08-17 | — | — | US | claimed |
| CN-1291649-A | Genetically engineered virus of Chinese ballworm | WUHAN INST OF VIRUSES CHINESE (CN) | 2001-04-18 | — | — | CN | claimed |
| EP-0763132-B1 | ASSAY FOR ENZYME ACTIVITY USING A MICROFLUOROMETRIC ASSAY | ISOLAB INC (US) | 2001-01-24 | — | — | EP | claimed |
| CN-1258741-A | Recombined Chinese bollworm virus | WUHAN INST OF VIROLOGY ACADEMI (CN) | 2000-07-05 | — | — | CN | claimed |
| CN-1208440-A | Process for producing sugar nucleotides and complex carbohydrates | KYOWA HAKKO KOGYO KK (JP) | 1999-02-17 | — | — | CN | claimed |
| CN-1207135-A | Process for producing sugar nucleotides and complex carbohydrates | KYOWA HAKKO KOGYO KK (JP) | 1999-02-03 | — | — | CN | claimed |
| EP-0870841-A1 | PROCESSES FOR PRODUCING SUGAR NUCLEOTIDES AND COMPLEX CARBOHYDRATES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1998-10-14 | — | — | EP | claimed |
| EP-0763132-A4 | ASSAY FOR ENZYME ACTIVITY USING A MICROFLUOROMETRIC ASSAY | ISOLAB INC (US) | 1997-06-18 | — | — | EP | claimed |
| EP-0763132-A1 | ASSAY FOR ENZYME ACTIVITY USING A MICROFLUOROMETRIC ASSAY | ISOLAB, INC. (US) | 1997-03-19 | — | — | EP | claimed |
| US-5538857-A | FLUORESCENCE | ISOLAB, INC. (US) | 1996-07-23 | — | — | US | claimed |
| WO-1995033072-A1 | ASSAY FOR ENZYME ACTIVITY USING A MICROFLUOROMETRIC ASSAY | ISOLAB, INC. (US) | 1995-12-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015668-A1 | COMPOSITION AND METHODS RELATED TO MODIFICATION OF 5 HYDROXYMETHYLCYTOSINE (5-hmC) | MTAP, PNP, NT5C3B | SLC28A1 269/4885SLC28A2 230/4885SLC29A1 183/4885 |
| US-20260022424-A1 | NUCLEIC ACID METHYLATION PROFILING METHOD | DNMT3A, DNMT3L, DNMT1 | SLC28A1 726/4885SLC28A2 381/4885SLC29A1 651/4885 |
| US-20260028668-A1 | DETECTION OF BASE MODIFICATIONS BY ENHANCING ELECTRICAL CONTRAST IN NANOPORES | NCL, PCNA, DNMT1 | SLC28A1 119/4885SLC28A2 113/4885SLC29A1 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.